Search results for "Quinolones"

showing 10 items of 103 documents

Antibiotic prophylaxis in patients who had undergone to prostate biopsy in between the EMA warning era: effects of fluoroquinolones in diabetic and n…

2022

Abstract Purpose To investigate the effects of different antibiotic prophylaxis regimens in patients with diabetes mellitus (DM) candidates to trans-rectal ultrasound-guided prostate biopsy (TRUSPB). Methods 143 outpatients with DM who underwent TRUSPB during the period 2018–2020 were selected from a cohort of 1150 patients in 3 different institutions. Exclusion criteria were allergies, concomitant anti-platelet therapies and uncontrolled DM. Different antibiotic prophylaxis regimens were adopted. Bacterial resistance levels to fluoroquinolones into the different communities were also collected. Univariable and multivariable binomial logistic regression analyses were used to assess the odds…

MaleAntibiotic resistanceUrologyBiopsyProstateRectumBacterial InfectionsAntibiotic ProphylaxisProstate biopsyAnti-Bacterial AgentsFluoroquinoloneAntibiotic prophylaxiDiabetes MellitusHumansAntibiotic prophylaxis; Antibiotic resistance; Fluoroquinolones; Infection; Prostate biopsyInfectionFluoroquinolonesWorld journal of urology
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use

2013

SummaryBackgroundIndacaterol is a once-daily, long-acting β2-agonist bronchodilator that improves dyspnoea and health status in patients with moderate-to-severe COPD. While its bronchodilator effects have been shown to be maintained in different patient subgroups, effects on clinical outcomes in certain subgroups are not yet defined.MethodsPost-hoc analysis of pooled clinical study data to investigate efficacy and safety of indacaterol compared with placebo and other long-acting bronchodilators (formoterol, salmeterol, open-label tiotropium) in patient subgroups defined by COPD severity (GOLD stage II or III; n = 4082) and ICS use at baseline (no/yes; n = 4088). Efficacy outcomes were troug…

MaleCopd patientsVital CapacityQuinolonesSeverity of Illness IndexPulmonary Disease Chronic ObstructiveForced Expiratory VolumeFormoterol FumarateBronchodilatorFormoterolSalmeterolSalmeterol XinafoateRandomized Controlled Trials as TopicIndacaterolCOPDMiddle AgedBronchodilator AgentsTreatment OutcomeEthanolaminesAnesthesiaIndansDrug Therapy CombinationFemaleSalmeterolmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classScopolamine DerivativesPlaceboDrug Administration ScheduleInternal medicineAdministration InhalationmedicineHumansCOPDAlbuterolTiotropium BromideAdrenergic beta-2 Receptor AgonistsGlucocorticoidsAgedbusiness.industryTiotropiummedicine.diseaserespiratory tract diseasesDyspneaLong actingIndacaterolFormoterolbusinessRespiratory Medicine
researchProduct

Pharmacokinetics, bioavailability and absorption of flumequine in the rat.

1999

Abstract The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0.94±0.04) and not significantly different from that found by the intraduodenal route (0.95±0.04). The rate of oral bioavailability, however, is slow ( k a =1.20±0.07 h −1 ; T max =2.0 h), but enough to maintain plasma levels above the minimal inhibitory concentration of the most common pathogens for an extended period of time (about 10 h). The reason for the oral absorption slowness could be a slow gastric emptying, an adsorption to the gastric mucosae, a precipitation in the gastric medium or any other feature concerning the stomach as the i…

MaleDuodenumPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalRandom AllocationPharmacokineticsAnti-Infective AgentsOral administrationEnterohepatic CirculationmedicineAnimalsRats WistarEnterohepatic circulationAntibacterial agentGastric emptyingChemistryStomachGeneral MedicineBioavailabilityRatsmedicine.anatomical_structureIntestinal AbsorptionFlumequineQuinolizinesBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Emergence of tularemia in France: paradigm of the Burgundy region

2011

International audience; We report three consecutive cases of tularemia occurring in Burgundy, France, a region previously considered not endemic for tularemia. The patients presented with varied and unspecific clinical manifestations. The epidemiological circumstances, especially the mode of contamination, were not particularly suggestive of tularemia. Serological diagnosis was delayed in two cases because of the lack of significant antibody titers at the time of admission. In contrast, a diagnosis could readily be obtained in all three cases by detection of Francisella tularensis DNA from clinical samples using PCR-based methods. These cases highlight the increased incidence and geographic…

MaleEpidemiologyMESH: Lymph NodesCommunicable Diseases EmergingSerologyTularemia0302 clinical medicineMESH: Early DiagnosisEpidemiologyDiagnosisMESH: Communicable Diseases Emerging030212 general & internal medicineMESH: DoxycyclineFrancisella tularensisTularemia0303 health sciencesMESH: TularemiaMESH: Middle AgedbiologyMESH: Real-Time Polymerase Chain ReactionIncidence (epidemiology)[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Antibody titerGeneral Medicinerespiratory systemMiddle Aged3. Good healthAnti-Bacterial AgentsInfectious DiseasesFrancisella tularensis DNADoxycyclineFemaleFranceFluoroquinolonesAdultDNA BacterialMicrobiology (medical)medicine.medical_specialtyReal-Time Polymerase Chain Reactioncomplex mixtures03 medical and health sciencesMESH: Francisella tularensisMESH: Anti-Bacterial AgentsmedicineHumansFrancisella tularensisMESH: Humans030306 microbiologyMESH: AdultMESH: Fluoroquinolonesbiology.organism_classificationmedicine.diseasebacterial infections and mycosesVirologyMESH: DNA BacterialMESH: MaleMESH: FranceEarly DiagnosisbacteriaLymph NodesMESH: FemaleReal-time PCRInternational Journal of Infectious Diseases
researchProduct

Biophysical Models as an Approach To Study Passive Absorption in Drug Development: 6-Fluoroquinolones

1995

A preliminary study attempting to assess and explain the intestinal absorption of a series of antibacterial 7-piperazinyl-6-fluoroquinolones is presented. The synthesis, n-octanol partition coefficients, intrinsic rat gut in situ absorption rate constants, and in vitro antibacterial activity data found for these homologous compounds are described. A fluorimetric, reverse-phase HPLC method was performed for the quantification of the quinolones in absorption and partition samples. Equations based on two classic biophysical absorption models are given for predicting the intrinsic absorption features of the series according to the partition data or merely single structural parameters. In situ a…

MaleIn situChemical PhenomenaBiophysicsAnalytical chemistryAdministration OralPharmaceutical ScienceModels BiologicalBiophysical PhenomenaIntestinal absorptionBiopharmaceuticsAnti-Infective AgentsPharmacokineticsIn vivoComputational chemistryAnimalsPartition (number theory)Rats WistarAbsorption (electromagnetic radiation)Chromatography High Pressure LiquidBacteriaChemistry PhysicalChemistryLipidsRatsMolecular WeightPartition coefficientIntestinal AbsorptionInjections IntravenousAntibacterial activityFluoroquinolonesJournal of Pharmaceutical Sciences
researchProduct

Synthesis, configuration, and calcium modulatory properties of enantiomerically pure 5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylates.

1992

Enantiomerically pure hexahydroquinolinones of the structural type 9 were prepared by a variation of the Hantzsch synthesis in which an optically active acetoacetate served as a chiral auxiliary reagent. Determinations of the de and ee values are described. The absolute configurations of the optically pure products were characterized by single-crystal X-ray analysis. The antipodes 9a and 9b exhibited calcium antagonistic activities on smooth musculature; the (S)-(-)-enantiomer 9b was the more potent compound with regard to the EC50 values which differed by a factor of 100; the intrinsic activity of 9b was 1.2, compared with a value of 0.54 for 9a. On the other hand, R-(+)-9a exerted positiv…

MaleIntrinsic activityGuinea PigsMolecular Conformationchemistry.chemical_elementCalciumQuinolonesMedicinal chemistrychemistry.chemical_compoundX-Ray DiffractionIleumDrug DiscoveryAnimalsHeart AtriaAortaChiral auxiliaryBicyclic moleculeMolecular StructureEnantioselective synthesisAbsolute configurationBiological activityStereoisomerismPapillary MusclesAtrial FunctionCalcium Channel BlockersElectric StimulationchemistryReagentMolecular MedicineFemaleMuscle ContractionJournal of medicinal chemistry
researchProduct

Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.

2013

Introduction Aripiprazole, an atypical antipsychotic drug with mixed antagonism and agonism on dopamine D2 and serotonin receptors, is a substrate of the efflux transporter P-glycoprotein (P-gp). Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination. Methods The motor behaviour of wild-type (WT) and P-gp deficient [abcb1ab(-/-)] mice was investigated on a RotaRod. Mice received acute injections of either aripirazole or ziprasidone. For comparison, the dopamine receptor antagonist haloperidol and serotonin receptor ligands buspirone and ketanserin were also applied. …

MaleKetanserinmedicine.drug_classAripiprazoleAtypical antipsychoticPharmacologyMotor ActivityQuinolonesRotarod performance testPiperazinesBuspironeMiceDopamine receptor D2medicineAnimalsPharmacology (medical)ZiprasidoneATP Binding Cassette Transporter Subfamily B Member 1Mice KnockoutChemistryGeneral MedicineBuspironeSerotonin Receptor AgonistsPsychiatry and Mental healthThiazolesDopamine receptorRotarod Performance TestHaloperidolAripiprazoleKetanserinSerotonin Antagonistsmedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Escherichia coli of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy

2012

Objectives: Poultry have been suggested as a reservoir for fluoroquinolone-resistant extraintestinal pathogenic Escherichia coli (ExPEC). Our aim was to investigate whether genotypes associated with ciprofloxacin and multidrug resistance were shared among human and avian E. coli. Methods: We compared 277 human ExPEC isolates from urinary tract infection (UTI) and sepsis (142 susceptible and 135 ciprofloxacin resistant) and 101 avian isolates (68 susceptible and 33 ciprofloxacin resistant) by antimicrobial resistance phenotype, phylogenetic group and multilocus sequence type (ST). Results: Most ciprofloxacin-resistant isolates from both human and avian sources were multidrug resistant. Human…

MaleMicrobiology (medical)TurkeysSettore MED/07 - Microbiologia E Microbiologia ClinicaAdolescentGenotypeBiologymedicine.disease_causeGroup AMicrobiologyAntibiotic resistanceDrug Resistance Multiple BacterialSepsisGenotypeEscherichia colimedicineAnimalsCluster AnalysisHumansPharmacology (medical)zoonosis urinary tract infections MLST molecular epidemiologyChildEscherichia coliEscherichia coli InfectionsPoultry DiseasesPharmacologyExtraintestinal Pathogenic Escherichia coliPhylogenetic treeInfantVirologyDrug Resistance MultipleAnti-Bacterial AgentsCiprofloxacinMultiple drug resistanceInfectious DiseasesItalyChild PreschoolUrinary Tract InfectionsFemaleChickensFluoroquinolonesMultilocus Sequence Typingmedicine.drug
researchProduct

Extended release and enhanced bioavailability of moxifloxacin conjugated with hydrophilic cellulose ethers.

2015

Macromolecular prodrugs (MPDs) of moxifloxacin were fabricated based on hydroxypropylcellulose (HPC) and hydroxyethylcellulose (HEC). UV/Vis spectrophotometry was employed to determine covalently loaded drug content (DC) of each conjugate. The degree of substitution (DS) of moxifloxacin attained ranged from 0.27 to 0.38 (HPC) and 0.19 to 0.26 (HEC) per anhydroglucose unit (AGU), respectively. Transmission electron microscopic analyses showed that HPC-moxifloxacin conjugates self-assembled into nanowires of ∼ 30 nm diameters while HEC-moxifloxacin conjugates self-assembled into nanoparticles of 150-350 nm. In vitro drug release studies revealed that 15 and 49% moxifloxacin release occurred f…

MalePolymers and PlasticsKineticsMoxifloxacinBiological Availability02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundPharmacokineticsMoxifloxacinSpectrophotometryMaterials ChemistrymedicineAnimalsheterocyclic compoundsProdrugsCelluloseCelluloseChromatographymedicine.diagnostic_testOrganic Chemistrybiochemical phenomena metabolism and nutritionProdrugbacterial infections and mycoses021001 nanoscience & nanotechnology0104 chemical sciencesBioavailabilityDrug LiberationKineticschemistryDelayed-Action PreparationsRabbits0210 nano-technologyHydrophobic and Hydrophilic Interactionsmedicine.drugConjugateFluoroquinolonesCarbohydrate polymers
researchProduct